The Korea Centers for Disease Control and Prevention said on Wednesday, South Korea confirmed 152 new coronavirus cases, with the total count now at 8,565.
The South reported 7 new deaths, bringing up the death toll to 91.
Further, the health institute showed that 407 more fully recovered coronavirus patients are released, with total cured people standing at 1,947.
Risk-aversion is sweeping the markets and the demand for the US dollar as well, as funding stress continues amid the coronavirus crisis.
USD/JPY rallies hard to renew three-week high at 109.48
S. Korea intervenes
Meanwhile, USD/KRW hit the highest since 2009 at 1,291.55, as the South Korean Finance Minister said the fall in the Korean won is excessive.
Citing some fx dealers, Reuters reports that S. Korea's fx authorities are seen selling dollars to curb won's fall after the official verbal intervention.
At the press time, the cross ticks down a few pips at 1,278, still up 1.90% on the day.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.